Investigator Charles C. Wykoff, M.D., Ph.D., discusses the mechanism of Zenkuda (tarcocimab) and why there is a need for new anti-vascular endothelial growth factor (VEGF) to treat patients with diabetic retinopathy.
Investigator Charles C. Wykoff, M.D., Ph.D., discusses the full results of the GLOW2 study, which found that Zenkuda (tarcocimab) resulted in improvement in diabetic retinopathy, including in patients who were taking GLP-1 agonists for their diabetes.
The Economics of Cell and Gene Therapy: Managing the Cost, Realizing the Value
Specific brainstem inhibitory neurons help the brain filter out distractions by suppressing competing sensory signals, allowing mice (and presumably humans) to stay focused.
A former radiation oncologist turned chief medical officer, Rex Hoffman, M.D., MBA, has spent the past several years expanding his leadership footprint across Providence Holy Cross Medical Center’s health system while authoring multiple books aimed at helping physicians navigate the transition into executive roles.
Marc Elia of Invyvid explains the difference between vaccines and monoclonal antibodies.
Cloud-based pharmacy benefit administration (PBA) platforms are providing transparency for pharmacies and patients.
In this closing segment, Drs. Lovly and Shaw synthesize the most important lessons from the 7-year CROWN update, address the study's remaining limitations and unanswered questions, and reflect on what this data means for the broader landscape of ALK-positive NSCLC care — from treatment guidelines to payer decision-making to patient survivorship.
Built from the experiences of patients, advocates and clinicians, a new MASH patient journey map offers a roadmap for navigating diagnosis and highlights the need for greater public understanding of the disease.
